Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725969 | 0.85 | ELANE (0.33) | — | |
| SCHEMBL15818033 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL7730649 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL6895243 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL5151400 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL2387294 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL4213128 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL5451160 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL7127383 | 0.83 | ELANE (0.32) | — | |
| SCHEMBL2388677 | 0.83 | ELANE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680298-B2 | Process for the preparation of orlistat | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-25 | — | — | US | claimed |
| US-20100179335-A1 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-15 | — | — | US | claimed |
| EP-2164839-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | Ranbaxy Laboratories Limited (IN) | 2010-03-24 | — | — | EP | claimed |
| WO-2008149321-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-11 | — | — | WO | claimed |
| US-8680298-B2 | Process for the preparation of orlistat | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-25 | — | — | US | disclosed |
| US-8680298-B2 | Process for the preparation of orlistat | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-25 | — | — | US | disclosed |
| US-20100179335-A1 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| US-20100179335-A1 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-2164839-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | Ranbaxy Laboratories Limited (IN) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164839-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | Ranbaxy Laboratories Limited (IN) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008149321-A3 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LAB LTD (IN) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008149321-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008149321-A2 | PROCESS FOR THE PREPARATION OF ORLISTAT | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-11 | — | — | WO | disclosed |
| US-7371741-B2 | Estradiol derivatives and pharmaceutical compositions using same | ENTREMED, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070135400-A1 | Estradiol derivatives | ENTREMED, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070010505-A1 | Methods of treating disease states using antiangiogenic agents | ENTREMED, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1633367-A2 | ANTIANGIOGENIC AGENTS | EntreMed, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005030120-A2 | ANTIANGIOGENIC AGENTS | ENTREMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050014737-A1 | Antiangiogenic agents | ENTREMED, INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179335-A1 | PROCESS FOR THE PREPARATION OF ORLISTAT | FAAH, HHAT, SOAT2 | ALDH1A1 591/4885TSHR 3465/4885 |
| US-20070135400-A1 | Estradiol derivatives | ESR2, NR5A1, ESRRB | ALDH1A1 414/4885TSHR 2011/4885 |
| US-20050014737-A1 | Antiangiogenic agents | VEGFA, TEK, FLT4 | ALDH1A1 666/4885TSHR 1972/4885 |
| US-20070010505-A1 | Methods of treating disease states using antiangiogenic agents | VEGFA, PGF, TEK | ALDH1A1 539/4885TSHR 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.